The Novo Nordisk Foundation has come up with more funding to help battle the scourge of antimicrobial resistance (AMR), putting $25 million into a non-profit accelerator p
Innoviva has moved a step closer to bringing the first novel antibiotic to market for gonorrhoea in decades after reporting positive results in a phase 3 trial.
The FDA has given a green light to Innoviva’s antibiotic combination Xacduro, which becomes the first drug specifically approved for pneumonia caused by hard-to-treat bact
With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a new treatment option after reporting phase 2a data with a novel antitubercular drug
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK's novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filing
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults